25 January 2024
BEXIMCO PHARMACEUTICALS
LIMITED
Payment of Cash
Dividend
Beximco Pharmaceuticals Limited
("Beximco Pharma", "BPL" or "the Company"; AIM Symbol: BXP, LEI
No.: 213800IMBBD6TIOQGB56), the fast-growing manufacturer of
generic pharmaceutical products and active pharmaceutical
ingredients, today announces that the 35% cash dividend of the
nominal value per ordinary share/GDR (Taka 3.50 per ordinary
share/GDR) for the year ended 30 June 2023, which was approved in
the Annual General Meeting ("AGM") held on 28 December 2023, has
been deposited with the custodian bank (HSBC) in Dhaka on 24
January 2024 for onward credit to respective GDR holders'
accounts.
For any queries regarding the credit
of dividend to respective accounts of holders of GDRs, please
contact the Depository (The Bank of New York Mellon)
representative, Mr. Vinu Kurian, at vinu.kurian@bnymellon.com.
For
further information please visit www.beximcopharma.com or enquire
to:
|
|
|
Beximco Pharma
|
|
S M Rabbur Reza, Chief Operating
Officer
Tel: +880 2 58611001, Ext.
20111
Mohammad Ali Nawaz, Chief Financial
Officer
Tel: +880 2 58611001, Ext.
20030
|
|
SPARK
Advisory Partners Limited (Nominated Adviser)
Mark Brady / Andrew Emmott
Tel: +44 (0)20 3368 3551 /
3555
|
|
SP
Angel Corporate Finance LLP (Broker)
Matthew Johnson
Tel: +44 (0) 20 3470 0470
|
|
FTI
Consulting
Simon Conway / Victoria Foster
Mitchell
Tel: +44 (0)20 3727 1000
|
Notes
to Editors
About
Beximco Pharmaceuticals Limited
Beximco Pharma is a leading
manufacturer and exporter of medicines based in Bangladesh. Since
its inception in 1976, the Company remains committed to health and
wellbeing of people across all the continents by providing access
to contemporary medicines. Company's broad portfolio of generics
encompasses diverse delivery systems such as tablets, capsules,
liquids, semi-solids, intravenous fluids, metered dose inhalers,
dry powder inhalers, sterile ophthalmic drops, insulins, prefilled
syringes, injectables, nebulizer solutions, oral soluble films etc.
The Company also undertakes contract manufacturing for
multinational and leading global generic pharmaceutical
companies.
Beximco Pharma′s state-of-the-art
manufacturing facilities are certified by global regulatory
authorities of USA, Europe, Australia, Canada, GCC and Latin
America, among others and it has a geographic footprint in more
than 50 countries. More than 5,700 employees are driving the
company towards achieving its aspiration to be among the most
admired companies in the world.